Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Zalando-Aktie -6,8%: Ist die schwache Bruttomarge ein Warnsignal? (Sharedeals) +++ ZALANDO Aktie +6,03%

NEUROCRINE Aktie

 >NEUROCRINE Aktienkurs 
136 EUR    +4.7%    (TradegateBSX)
Ask: 138 EUR / 37 Stück
Bid: 135.35 EUR / 40 Stück
Tagesumsatz: 199 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
NEUROCRINE Aktie über LYNX handeln
>NEUROCRINE Performance
1 Woche: +0,9%
1 Monat: +3,6%
3 Monate: -9,8%
6 Monate: +16,5%
1 Jahr: +5,7%
laufendes Jahr: +7,1%
>NEUROCRINE Aktie
Name:  NEUROCRINE BIOSCI. DL-001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US64125C1099 / 900964
Symbol/ Ticker:  NB3 (Frankfurt) / NBIX (NASDAQ)
Kürzel:  FRA:NB3, ETR:NB3, NB3:GR, NASDAQ:NBIX
Index:  -
Profil:  Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for mo..
>Volltext..
Marktkapitalisierung:  13306.82 Mio. EUR
Unternehmenswert:  13317.34 Mio. EUR
Umsatz:  3023.1 Mio. EUR
EBITDA:  764.76 Mio. EUR
Nettogewinn:  632.15 Mio. EUR
Gewinn je Aktie:  6.31 EUR
Schulden:  360.02 Mio. EUR
Liquide Mittel:  297.84 Mio. EUR
Operativer Cashflow:  752.39 Mio. EUR
Bargeldquote:  0.45
Umsatzwachstum:  38.65%
Gewinnwachstum:  108.93%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  NEUROCRINE
Letzte Datenerhebung:  03.11.26
>NEUROCRINE Kennzahlen
Aktien/ Unternehmen:
Aktien: 101.65 Mio. St.
Frei handelbar: 98.79%
Rückkaufquote: -0.84%
Mitarbeiter: 2000
Umsatz/Mitarb.: 1.28 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 43.2%
Bewertung:
KGV: 21.68
KGV lG: 20.36
KUV: 4.45
KBV: 4.07
PEG-Ratio: 0.21
EV/EBITDA: 17.41
Rentabilität:
Bruttomarge: 97.48%
Gewinnmarge: 20.91%
Operative Marge: 23.9%
Managementeffizenz:
Gesamtkaprendite: 15.26%
Eigenkaprendite: 22.09%
>NEUROCRINE Peer Group
Gesundheit, Neurologische Erkrankungen/ Schlaganfälle, Endokrine Erkrankungen (Hormonstörungen)
 
03.11.26 - 05:36
Neurocrine (NBIX) Q3 2026 Earnings Call Transcript (Fool)
 
Record $1.1B revenue marks transformative quarter for diversified biotech....
03.11.26 - 03:12
Neurocrine expects double-digit 2027 INGREZZA volume growth despite mid- to high single-digit net pricing headwinds (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.11.26 - 03:00
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
 
Neurocrine (NBIX) delivered earnings and revenue surprises of +29.53% and +8.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...
03.11.26 - 02:15
Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
 
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....
02.11.26 - 23:54
Neurocrine Biosciences übertrifft Prognosen für das 3. Quartal 2026 – Aktie legt nachbörslich kräftig zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.11.26 - 23:12
Neurocrine Biosciences Inc Reveals Drop In Q3 Income (AFX)
 
WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) revealed earnings for third quarter that Drops, from the same period last yearThe company's bottom line came in at $206.5 million, or $1.96......
02.11.26 - 22:54
Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results (PR Newswire)
 
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third......
30.10.26 - 13:33
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia (PR Newswire)
 
BootCAHmp® delivers evidence-based education to strengthen understanding of classic congenital adrenal hyperplasia through interactive learning and real-world patient cases DiscoverCAH™ provides immersive virtual experiences to expand knowledge of classic congenital adrenal hyperplasia......
26.10.26 - 16:30
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? (Zacks)
 
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
25.10.26 - 11:48
Where Will Neurocrine Biosciences Be in 5 Years? (Fool)
 
Neurocrine's expanding drug portfolio could drive substantial growth through 2031....
22.10.26 - 22:09
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome (PR Newswire)
 
Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patients and families beyond obesity-related complications The manuscript underscores the......
16.10.26 - 15:30
Neurocrine Presents Real-World Data Mapping Evolving Impact Of Congenital Adrenal Hyperplasia (AFX)
 
WASHINGTON (dpa-AFX) - Neurocrine Biosciences (NBIX) reported real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individu......
16.10.26 - 14:33
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia (PR Newswire)
 
Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showed growth and bone-age monitoring in childhood; puberty and reproductive health concerns......
12.10.26 - 22:06
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results (PR Newswire)
 
Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.......
30.09.26 - 14:33
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference (PR Newswire)
 
PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will capture caregiver-reported information to better understand the experience and burden of......
28.09.26 - 22:09
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer (PR Newswire)
 
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and currently serves as a Strategic Advisor, will rejoin the Company's executive management team as......
16.09.26 - 00:01
Insiderhandel: Chief Corp. Affairs Officer verkauft Aktien von Neurocrine Biosciences im Wert von 130051 USD (Insiderkauf)
 
Boyer, David W. - Vorstand - Tag der Transaktion: 2026-09-14...
16.09.26 - 00:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Neurocrine Biosciences im Wert von 363285 USD (Insiderkauf)
 
Abernethy, Matt - Vorstand - Tag der Transaktion: 2026-09-14...
11.09.26 - 08:01
Insiderhandel: Chief Commercial Officer verkauft Aktien von Neurocrine Biosciences im Wert von 333030 USD (Insiderkauf)
 
Benevich, Eric - Vorstand - Tag der Transaktion: 2026-09-09...
10.09.26 - 15:42
Neurocrine Biosciences auf Cantor-Gesundheitskonferenz: Wachstum auf breiterer Basis, aber Preisdruck bei INGREZZA (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Bock ist ein Tier, welches auch als Bier getrunken werden kann. - Wilhelm Busch
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!